Balance Sheet
Cash Flow Statement
AmortizationAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Gains from Investment Securities (2020 - 2024)

Historic Gains from Investment Securities for Legend Biotech (LEGN) over the last 6 years, with Q3 2025 value amounting to -$2.1 million.

  • Legend Biotech's Gains from Investment Securities fell 409387.76% to -$2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$16.3 million, marking a year-over-year decrease of 94720.97%. This contributed to the annual value of -$663000.0 for FY2023, which is 1180.44% down from last year.
  • Per Legend Biotech's latest filing, its Gains from Investment Securities stood at -$2.1 million for Q3 2025, which was down 409387.76% from -$15.6 million recorded in Q2 2025.
  • In the past 5 years, Legend Biotech's Gains from Investment Securities ranged from a high of $896000.0 in Q4 2024 and a low of -$15.6 million during Q2 2025
  • Its 5-year average for Gains from Investment Securities is -$1.5 million, with a median of -$44000.0 in 2021.
  • In the last 5 years, Legend Biotech's Gains from Investment Securities skyrocketed by 125897.44% in 2022 and then plummeted by 409387.76% in 2025.
  • Legend Biotech's Gains from Investment Securities (Quarter) stood at $40000.0 in 2021, then crashed by 1582.5% to -$593000.0 in 2022, then decreased by 11.8% to -$663000.0 in 2023, then soared by 235.14% to $896000.0 in 2024, then tumbled by 329.35% to -$2.1 million in 2025.
  • Its Gains from Investment Securities stands at -$2.1 million for Q3 2025, versus -$15.6 million for Q2 2025 and $473000.0 for Q1 2025.